BMS-707035 |CAS 729607-74-3|DC Chemicals

Cas No.:	729607-74-3
Chemical Name:	Bms-707035
Synonyms:	BMS-707035;2-(1,1-dioxothiazinan-2-yl)-N-[(4-fluorophenyl)methyl]-5-hydroxy-1-methyl-6-oxopyrimidine-4-carboxamide;BMS707035;BMS 707035;7PR4P7YOKT;N-[(4-Fluorophenyl)methyl]-1,6-dihydro-5-hydroxy-1-methyl-6-oxo-2-(tetrahydro-1,1-dioxido-2H-1,2-thiazin-2-yl)-4-pyrimidinecarboxamide;2-(1,1-dioxido-1,2-thiazinan-2-yl)-N-(4-fluorobenzyl)-5-hydroxy-1-methyl-6-oxo-1,6-dihydropyrimidine-4-carboxamide;HIV Integrase Inhibitor;VNIWZCGZPBJWBI-UHFFFAOYSA-N;HMS3654F19;BCPP000324;BCP02412;ABP000916;s1366;RL04775;BCP9000435;NCGC
SMILES:	S1(C([H])([H])C([H])([H])C([H])([H])C([H])([H])N1C1=NC(C(N([H])C([H])([H])C2C([H])=C([H])C(=C([H])C=2[H])F)=O)=C(C(N1C([H])([H])[H])=O)O[H])(=O)=O
Formula:	C₁₇H₁₉FN₄O₅S
M.Wt:	410.4200
Purity:	>98%
Sotrage:	2 years -20°C Powder, 2 weeks 4°C in DMSO, 6 months -80°C in DMSO

Description:

BMS-707035 is an HIV-1 integrase (IN) inhibitor with an IC50 value of 15 nM. IC50 Value: 15 nMTarget: HIV IntegraseBMS-707035 was scheduled to be evaluated in a Phase II study to assess the antiretroviral activity, safety, pharmacodynamics, and pharmacokinetics in 50 HIV-infected subjects using a 10-day randomized, double-blind, placebo-controlled, ascending multiple-dose study design.

References:

[1]. Cotelle P.,3-Hydroxy-6,7-dihydropyrimido[2,1-c][1,4]oxazin-4(9H)-ones as new HIV-1 integrase inhibitors WO2011046873 A1.,Expert Opin Ther Pat. 2011 Nov;21(11):1799-804. [2]. Al-Mawsawi LQ, Al-Safi RI, Neamati N.,Anti-infectives: clinical progress of HIV-1 integrase inhibitors.,Expert Opin Emerg Drugs. 2008 Jun;13(2):213-25. [3]. Dayam R, Al-Mawsawi LQ, Neamati N.,HIV-1 integrase inhibitors: an emerging clinical reality.,Drugs R D. 2007;8(3):155-68. [4]. Dicker IB, et al. Changes to the HIV long terminal repeat and to HIV integrase differentially impact HIV integrase assembly, activity, and the binding of strand transfer inhibitors. J Biol Chem. 2007 Oct 26;282(43):31186-96.

MSDS

COA

LOT NO.	DOWNLOAD

2018-0101
2018-0101

Cat. No.	Product name	Field of application
DC11397	TAK-779	TAK-779 is a potent and selective nonpeptide antagonist of CCR5 and CXCR3, with a Ki of 1.1 nM for CCR5, and effectively and selectively inhibits R5 HIV-1, with EC50 and EC90 of 1.2 nM and 5.7 nM, respectively, in MAGI-CCR5 cells.
DC7266	Rilpivirine(R 278474, TMC 278)	Rilpivirine(R 278474, TMC 278) is a type of anti-HIV medicine called a non-nucleoside reverse transcriptase inhibitor (NNRTI).
DC5902	Emtricitabine	Emtricitabine is a nucleoside analogue which inhibits the reverse nucleoside transcriptase enzyme. Structurally this antiviral agent is similar to Lamivudine. This agent is effective at targeting HIV and HBV viruses since these viruses replicate in a reve
DC10250	Dolutegravir Sodium	Dolutegravir is a HIV integrase inhibitor with IC50 of 2.7 nM.
DC7273	Dolutegravir	Dolutegravir (DTG, GSK1349572) is an integrase inhibitor(IC50= 2.7 nM), modest activity against raltegravir-resistant signature mutants Y143R, Q148K, N155H, and G140S/Q148H.
DC9700	BMS-707035	BMS-707035 is a potent, specific, and reversible HIV-I integrase (IN) inhibitor that blocks HIV IN strand transfer activity.
DC10890	Bictegravir	Bictegravir is a novel, potent inhibitor of HIV-1 integrase with an IC50 of 7.5 nM.
DC3150	Atazanavir	Atazanavir is a HIV protease inhibitor with Ki of 2.66 nM.